Diabetes – Talk Bio

Actionable Insights Powered by AI

Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil

2 weeks ago talkbio0Tagged Brazil, Claros facility, Diabetes, Glucagon-Like Peptide 1, Investments, Montes, Nordisk, Obesity, Ozempic, pharmaceutical manufacturing, production, Wegovy

Novo Nordisk , GLP-1 production , Brazil investment , Wegovy and Ozempic , Diabetes treatment , Obesity treatment , Montes Claros facility , Pharmaceutical manufacturing

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

2 months ago talkbio0Tagged alpha 1-antitrypsin, Axplora, biology (field), CDMO, Chromatography, Diabetes, expansion, France, Glucagon-Like Peptide 1, Manufacturing, Mourenx, Obesity, production

Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies

FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

3 months ago talkbio0Tagged Agonist, Approved, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes, GLP-1 receptor, Kidney Diseases, Ozempic, Risk, semaglutide, United States Food and Drug Administration

Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist

Novo Nordisk and Valo Health Expand AI-Driven Collaboration to Develop Novel Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, biotech, Cardiovascular Diseases, Computational Technique, Diabetes, Drug Development, Nordisk, Obesity, Valo Health

Novo Nordisk, Valo Health, AI, Obesity, Type 2 Diabetes, Cardiovascular Disease, Drug Development, Computational Biotech

Sana Biotechnology’s Revolutionary Type 1 Diabetes Therapy Triggers Stock Surge

3 months ago talkbio0Tagged Diabetes, Hypoimmune Technology, Immune-Evading Therapy, Sana Biotechnology, Stock Surge

Sana Biotechnology, Type 1 Diabetes, Immune-Evading Therapy, Stock Surge, Hypoimmune Technology

Abbott and Dexcom Reach 10-Year Settlement Over Diabetes Sensor Patent Disputes

4 months ago talkbio0Tagged abbott, Continuous glucose monitoring, Dexcom, Diabetes, Legal patent, Litigation, sensor (device), settlement, truce

Abbott, Dexcom, diabetes sensor, patent litigation, settlement, 10-year truce, continuous glucose monitoring (CGM)

EU Regulator to Investigate Potential Link Between Ozempic and Rare Eye Condition NAION

4 months ago talkbio0Tagged Agencies, Diabetes, European (ethnic group), Evaluation, NAION, Nordisk, Ozempic, semaglutide

Ozempic, NAION, European Medicines Agency, Novo Nordisk, semaglutide, eye disorder, diabetes drug, investigation

Eli Lilly Invests $3 Billion in Wisconsin Manufacturing Expansion to Meet Growing Demand for Diabetes and Obesity Medicines

5 months ago talkbio0Tagged Diabetes, Eli, Eli Lilly, expansion, Investments, Manufacturing, Obesity, Surgical construction, Wisconsin

Eli Lilly, Wisconsin, manufacturing expansion, diabetes, obesity, pharmaceuticals, investment, job creation

Embecta Discontinues Insulin Patch Pump Program Amid Restructuring Efforts

5 months ago talkbio0Tagged Diabetes, Discontinuation (procedure), Embecta, insulin patch, pump (device), restructuring, Technology

Embecta, insulin patch pump, discontinuation, restructuring, layoffs, diabetes technology

Medtronic Advances Diabetes Management with FDA Clearance of InPen App and Launch of Smart MDI System

5 months ago talkbio0Tagged Administration occupational activities, Clearance, Continuous glucose monitoring, Diabetes, InPen, insulin therapy, Medtronic, Simplera, Smart MDI system, United States Food and Drug Administration

Medtronic, FDA clearance, InPen app, Smart MDI system, diabetes management, insulin therapy, continuous glucose monitoring (CGM), Simplera CGM